Japanese Dose-Response Study of Rimonabant in Obese Patients
NCT00459004
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
527
Enrollment
INDUSTRY
Sponsor class
Conditions
Obesity
Interventions
DRUG:
rimonabant (SR141716)
Sponsor
Sanofi